Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Exercise as a therapeutic tool to prevent mitochondrial degeneration in nonalcoholic steatohepatitis.

Gonçalves IO, Oliveira PJ, Ascensão A, Magalhães J.

Eur J Clin Invest. 2013 Nov;43(11):1184-94. doi: 10.1111/eci.12146. Epub 2013 Sep 5. Review.

PMID:
24033085
2.

Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

Begriche K, Igoudjil A, Pessayre D, Fromenty B.

Mitochondrion. 2006 Feb;6(1):1-28. Epub 2006 Jan 5. Review.

PMID:
16406828
3.

Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis.

Verbeek J, Lannoo M, Pirinen E, Ryu D, Spincemaille P, Vander Elst I, Windmolders P, Thevissen K, Cammue BP, van Pelt J, Fransis S, Van Eyken P, Ceuterick-De Groote C, Van Veldhoven PP, Bedossa P, Nevens F, Auwerx J, Cassiman D.

Gut. 2015 Apr;64(4):673-83. doi: 10.1136/gutjnl-2014-306748. Epub 2014 Jun 10.

PMID:
24917551
4.

Endoplasmic Reticulum Stress Response in Non-alcoholic Steatohepatitis: The Possible Role of Physical Exercise.

Passos E, Ascensão A, Martins MJ, Magalhães J.

Metabolism. 2015 Jul;64(7):780-92. doi: 10.1016/j.metabol.2015.02.003. Epub 2015 Feb 23. Review.

PMID:
25838034
5.

Etiopathogenesis of nonalcoholic steatohepatitis.

Chitturi S, Farrell GC.

Semin Liver Dis. 2001;21(1):27-41. Review.

PMID:
11296694
6.

Physical exercise prevents and mitigates non-alcoholic steatohepatitis-induced liver mitochondrial structural and bioenergetics impairments.

Gonçalves IO, Passos E, Rocha-Rodrigues S, Diogo CV, Torrella JR, Rizo D, Viscor G, Santos-Alves E, Marques-Aleixo I, Oliveira PJ, Ascensão A, Magalhães J.

Mitochondrion. 2014 Mar;15:40-51. doi: 10.1016/j.mito.2014.03.012. Epub 2014 Apr 13.

PMID:
24727595
7.

Exercise alters liver mitochondria phospholipidomic profile and mitochondrial activity in non-alcoholic steatohepatitis.

Gonçalves IO, Maciel E, Passos E, Torrella JR, Rizo D, Viscor G, Rocha-Rodrigues S, Santos-Alves E, Domingues MR, Oliveira PJ, Ascensão A, Magalhães J.

Int J Biochem Cell Biol. 2014 Sep;54:163-73. doi: 10.1016/j.biocel.2014.07.011. Epub 2014 Jul 23.

PMID:
25063232
8.

Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management.

Başaranoğlu M, Örmeci N.

Turk J Gastroenterol. 2014 Apr;25(2):127-32. doi: 10.5152/tjg.2014.7675. Review.

9.

The ins and outs of mitochondrial dysfunction in NASH.

Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D.

Diabetes Metab. 2004 Apr;30(2):121-38. Review.

PMID:
15223984
10.

The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis.

Ucar F, Sezer S, Erdogan S, Akyol S, Armutcu F, Akyol O.

Redox Rep. 2013;18(4):127-33. doi: 10.1179/1351000213Y.0000000050. Epub 2013 Jun 5. Review.

PMID:
23743495
11.

Non-alcoholic steatohepatitis in children.

Nanda K.

Pediatr Transplant. 2004 Dec;8(6):613-8. Review.

PMID:
15598336
12.

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.

Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN.

Gastroenterology. 2001 Apr;120(5):1183-92.

PMID:
11266382
13.

Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease.

Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B.

Hepatology. 2013 Oct;58(4):1497-507. doi: 10.1002/hep.26226. Epub 2013 Aug 7. Review.

PMID:
23299992
14.

Perspectives on Treatment for Nonalcoholic Steatohepatitis.

Lassailly G, Caiazzo R, Pattou F, Mathurin P.

Gastroenterology. 2016 Jun;150(8):1835-48. doi: 10.1053/j.gastro.2016.03.004. Epub 2016 Mar 10. Review.

PMID:
26971824
15.

Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease.

Paradies G, Paradies V, Ruggiero FM, Petrosillo G.

World J Gastroenterol. 2014 Oct 21;20(39):14205-18. doi: 10.3748/wjg.v20.i39.14205. Review.

16.

Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis.

Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, Herder C, Carstensen M, Krausch M, Knoefel WT, Schlensak M, Roden M.

Cell Metab. 2015 May 5;21(5):739-46. doi: 10.1016/j.cmet.2015.04.004.

17.

[Nonalcoholic steatohepatitis: pathogenesis and treatment].

Park SH.

Korean J Hepatol. 2008 Mar;14(1):12-27. doi: 10.3350/kjhep.2008.14.1.12. Review. Korean.

18.

Current pharmacological treatment of nonalcoholic fatty liver.

Portincasa P, Grattagliano I, Palmieri VO, Palasciano G.

Curr Med Chem. 2006;13(24):2889-900. Review.

PMID:
17073635
20.

Mitochondrial dysfunction in nonalcoholic steatohepatitis.

Serviddio G, Bellanti F, Vendemiale G, Altomare E.

Expert Rev Gastroenterol Hepatol. 2011 Apr;5(2):233-44. doi: 10.1586/egh.11.11. Review.

PMID:
21476918

Supplemental Content

Support Center